Institute Of Biomedical Stock Fundamentals
MRES Stock | USD 0.01 0.0004 4.04% |
Institute of Biomedical fundamentals help investors to digest information that contributes to Institute's financial success or failures. It also enables traders to predict the movement of Institute Pink Sheet. The fundamental analysis module provides a way to measure Institute's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Institute pink sheet.
Institute |
Institute of Biomedical Company Shares Outstanding Analysis
Institute's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Institute Shares Outstanding | 66.28 M |
Most of Institute's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Institute of Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Based on the latest financial disclosure, Institute of Biomedical has 66.28 M of shares currently outstending. This is 63.29% lower than that of the Healthcare sector and 37.97% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 88.41% higher than that of the company.
Institute of Biomedical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Institute's current stock value. Our valuation model uses many indicators to compare Institute value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Institute competition to find correlations between indicators driving Institute's intrinsic value. More Info.Institute of Biomedical is rated top company in current valuation category among its peers. It also is considered to be number one stock in shares outstanding category among its peers creating about 333.33 of Shares Outstanding per Current Valuation. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Institute's earnings, one of the primary drivers of an investment's value.Institute Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Institute's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Institute could also be used in its relative valuation, which is a method of valuing Institute by comparing valuation metrics of similar companies.Institute is currently under evaluation in shares outstanding category among its peers.
Institute Fundamentals
Current Valuation | 198.84 K | |||
Shares Outstanding | 66.28 M | |||
Price To Book | 0.69 X | |||
Revenue | 1.41 M | |||
Net Income | 564.67 K | |||
Cash Flow From Operations | 2.06 M | |||
Beta | 1.71 | |||
Market Capitalization | 639.61 K | |||
Total Asset | 5.28 M | |||
Retained Earnings | (55.58 M) | |||
Current Asset | 2.56 M | |||
Current Liabilities | 3.8 M | |||
Z Score | -14.0 | |||
Net Asset | 5.28 M |
About Institute Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Institute of Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Institute using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Institute of Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Institute of Biomedical Research Corp. was founded in 2010 and is based in Podgorica, Montenegro with a representative office in Montreal, Canada. Institute is traded on OTC Exchange in the United States.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Institute Pink Sheet Analysis
When running Institute's price analysis, check to measure Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Institute is operating at the current time. Most of Institute's value examination focuses on studying past and present price action to predict the probability of Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Institute's price. Additionally, you may evaluate how the addition of Institute to your portfolios can decrease your overall portfolio volatility.